SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen NASDAQ:NGEN, a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the third quarte…

NGEN

Related stories